Penumbra Inc. (PEN)
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand
PEN reports better-than-expected earnings and revenues in the first quarter of 2025.
Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN ) Q1 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Cecilia Furlong - Business Development & IR Adam Elsesser - Chairman & CEO Maggie Yuen - CFO Jason Mills - EVP, Strategy Conference Call Participants Robbie Marcus - JPMorgan Lei Huang - Wells Fargo Pito Chickering - Deutsche Bank Macauley Kilbane - William Blair Bill Plovanic - Canaccord Travis Steed - Bank of America Ryan Zimmerman - BTIG Kallum Titchmarsh - Morgan Stanley Richard Newitter - Truist Matthew O'Brien - Piper Sandler David Rescott - Baird Operator Good afternoon. My name is Tameka and I will be your conference operator today.
Penumbra (PEN) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again
Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
PEN continues to attract investor interest with its strong Thrombectomy business and portfolio expansion efforts.
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues
Penumbra expects to materially increase both revenues and profitability in the company's international business in the next few years.
Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail
Penumbra is still in the early stages of its journey to bring the company's proprietary thrombectomy technologies to patients in the United States and around internationally.
Penumbra (PEN) Upgraded to Buy: Here's Why
Penumbra (PEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises
Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.
Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Larry Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Bill Plovanic - Canaccord Richard Newitter - Truist Securities Samantha Kurtz - Piper Sandler Michael Sarcone - Jefferies Ryan Zimmerman - BTIG Shagun Singh - RBC Capital Markets Michael Kratky - Leerink Partners Operator Good afternoon. My name is Rob and I will be your conference operator today.
Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
